Analyst Research
| Report Title | Price |
|---|---|
|
Provider: S&P Capital IQ Factual Report
|
$127.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cubist Pharmaceuticals, Inc. Announces Appointment Of President
Cubist Pharmaceuticals, Inc. announced that Robert J. Perez, currently Executive Vice President and Chief Operating Officer (COO), has been named President and COO, and Michael Tomsicek, currently Vice President of Corporate Finance, has been named Senior Vice President and Deputy Chief Financial Officer. In addition, Thomas Rollins has been appointed Senior Vice President of Program and Portfolio Management.
Latest Developments for Cubist Pharmaceuticals Inc
- Cubist Pharmaceuticals Inc Reaffirms FY 2013 Revenue Guidance; Issues FY 2013 Operating Income Guidance Below Analysts' Estimates-Conference Call
- Cubist Pharmaceuticals Inc Announces Exclusive Option To Acquire Adynxx, Inc
- Cubist Pharmaceuticals Inc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates-Conference Call
- Cubist Pharmaceuticals Inc Raises Low End Of Prior FY 2012 Revenue Guidance To A Range In Line With Analysts' Estimates-Conference Call
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters